Charlotte Casebourne Departs Theolytics for New Venture

OXFORD, England, July 12, 2024 -- Theolytics, a biotechnology company in clinical stages dedicated to using viruses to fight diseases, has announced a significant change in its leadership. Charlotte Casebourne Stock, one of the company's Co-Founders and the current CEO, will be transitioning to an advisory role. Mike Grey, the Executive Chair of the board of directors, will take over the leadership responsibilities in the interim.

Charlotte Casebourne Stock reflected on her journey, stating, "Leading Theolytics from its inception in 2017 to treating the first ovarian cancer patient with our lead oncolytic virus candidate, THEO-260, has been incredibly rewarding. My goal has always been to drive equitable access to healthcare innovation and to build sustainable companies. With the significant progress we've made and the support from our investors for Theolytics' lead clinical program, I feel it’s the right time for me to start a new chapter aligned with my personal mission."

Mike Grey expressed his gratitude for Charlotte's contributions, saying, "On behalf of the board and Theolytics' investors, we extend our heartfelt appreciation to Charlotte. Theolytics owes its strong position today to her leadership. Over $40 million in both dilutive and non-dilutive capital was raised under her guidance, and within seven years, the company has progressed into clinical stages. We respect her decision to explore new entrepreneurial opportunities and wish her the best. I am excited to work with her as an advisor and to continue collaborating with Theolytics' Board and team to execute our promising strategy."

Theolytics focuses on developing next-generation oncolytic viral therapies, adopting a novel approach to create effective, targeted candidates suited for systemic intravenous delivery. The company aims to provide better outcomes for patients suffering from ovarian cancer by advancing its lead program through clinical development. Theolytics is supported by prominent international life sciences investors, including M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures, and The University of Oxford.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!